Sign in
Taking people in United KingdomPhase 1

Testing Targeted Treatments in Metastatic Colorectal Cancer by Tumor Marker

Tests targeted drugs and immunotherapy in adults with colorectal cancer that has spread.

Key facts

Who runs it
Hoffmann-La Roche
Where
Cambridge, Cardiff, London, Manchester, and Sutton, United KingdomSee the 8 sitesAlso in 10 other countries, 75 sites
Registry title
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Status
Recruiting
Phase
Phase 1
People taking part
542 people, planned
Started
22 Oct 2021
Expected to end
31 Aug 2030
Type of study
Interventional, 10 groups
Treatments tested
  • Inavolisib
  • Bevacizumab
  • Cetuximab
  • Atezolizumab
  • Tiragolumab
  • SY-5609
  • Divarasib
  • FOLFOX
  • FOLFIRI
  • FoundationOne®Liquid CDx
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with colorectal cancer that has spread. Their tumors must test positive for a specific biomarker, and they must have had earlier treatment for the spread disease.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Metastatic (spread) adenocarcinoma of the colon or rectum, confirmed by tissue examination. At least one measurable tumor is needed.
Earlier treatment
Must have had earlier therapies for metastatic disease. Cannot have had any anti-cancer drug treatment within 2 weeks or 5 half-lives (whichever is shorter), or an investigational therapy within 28 days, before starting.
Biomarker or test result
The tumor must be biomarker positive as defined for the treatment arm, shown by a validated test or a blood-based FoundationOne Liquid CDx test.

Main reasons for not taking part

  • Taking part in another interventional clinical trial
  • Pregnant or breastfeeding, or planning to become pregnant
  • Brain metastases that cause symptoms, are untreated or are getting worse
  • Severe infection within 4 weeks before starting, or active infection that could affect safety
  • Another cancer within the last 2 years, with some exceptions

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Signed cohort-specific Informed Consent Form
  • Age >= 18 years at time of signing Informed Consent Form
  • Biomarker eligibility as determined by:; A validated test approved by local health authorities for detection of the specified biomarkers/mutations; A validated test performed at a College of American Pathologists/clinical laboratory improvement amendments (CAP/CLIA) -certified or equivalently accredited diagnostic laboratory using a validated test for detection of the specified biomarkers; Prior test results completed before signing cohort-specific Informed Consent Form or local test results generated prior to or during screening, and availability of a full report of the testing results OR; Blood-based FoundationOne Liquid CDx biomarker eligibility test result generated prior to or during screening or, in case of re-enrollment after treatment discontinuation, prior to starting a new anti-cancer therapy
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of <= 1
  • Life expectancy >= 3 months, as determined by the investigator
  • Histologically confirmed adenocarcinoma originating from the colon or rectum
  • Metastatic disease
  • Prior therapies for metastatic disease
  • Ability to comply with the study protocol, in the investigators judgment
  • Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Baseline tumor tissue samples will be collected from all participants for exploratory biomarker research
  • Adequate hematologic and organ function within 14 days prior to initiation of study treatment
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures
  • For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm

Who cannot take part

  • Any systemic anti-cancer treatment within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study treatment
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety
  • Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
  • Requirement for treatment with any medicinal product that contraindicates the use of any of the study treatments, may interfere with the planned treatment, affects participant compliance, or puts the patient at higher risk for treatment-related complications
  • Clinically significant and active liver disease
  • History of leptomeningeal disease or carcinomatous meningitis
  • History of malignancy other than CRC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
  • History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study or confounds the ability to interpret data from the study
  • Negative HIV test at screening, with the following exception: Participants with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count greater than or equal to 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months
  • Any other disease, unresolved toxicity from prior therapy, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
  • Current participation or enrollment in another interventional clinical trial. Participants who are participating in the follow-up period of an interventional clinical trial are eligible for the study
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
  • Uncontrolled tumor-related pain
  • Uncontrolled or symptomatic hypercalcemia
  • Symptomatic, untreated, or actively progressing CNS metastases

Where in United Kingdom

Also in 10 other countries, 75 sites

  • Addenbrookes HospitalCambridge, United KingdomTaking people
  • Velindre Cancer CentreCardiff, United KingdomTaking people
  • Imperial College Healthcare NHS TrustLondon, United KingdomTaking people
  • Royal Marsden Hospital;Dept of Med-OncLondon, United KingdomTaking people
  • Sarah Cannon Research InstituteLondon, United KingdomTaking people
  • Royal Free HospitalLondon, United KingdomNo longer taking part
  • The Christie NHS Foundation TrustManchester, United KingdomTaking people
  • Royal Marsden HospitalSutton, United KingdomTaking people

About the trial

What the trial wants to find out

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

The 10 groups in the trial

  • Inavolisib + CetuximabTreatment being tested

    Participants will receive 9 milligrams (mg) of inavolisib by mouth once daily (QD) on Days 8-28 of Cycle 1, then QD on Days 1-28 from Cycle 2 onwards (1 cycle=28 days). Participants will also receive cetuximab intravenous (IV) infusion 400 mg/m2 body surface area on Day 1 of Cycle 1. All subsequent weekly (QW) doses will be 250 mg/m2 each. This arm is closed.

    Treatment: Inavolisib, Cetuximab, and FoundationOne®Liquid CDx

  • Inavolisib + BevacizumabTreatment being tested

    Participants will receive 9 mg of inavolisib by mouth QD combined with bevacizumab 15 milligram/kilogram (mg/kg) IV once every three weeks (Q3W) on Day 1 of each cycle (1 cycle=21 days). This arm is closed.

    Treatment: Inavolisib, Bevacizumab, and FoundationOne®Liquid CDx

  • Atezolizumab + Tiragolumab + BevacizumabTreatment being tested

    Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle, combined with tiragolumab at a dose of 600 mg IV infusion on Day 1 of each cycle and bevacizumab IV infusion at a dose of 15 mg/kg on Day 1 of each cycle. (Cycle length=21 days) This arm is active, and not recruiting participants.

    Treatment: Bevacizumab, Atezolizumab, Tiragolumab, and FoundationOne®Liquid CDx

  • Atezolizumab + TiragolumabTreatment being tested

    Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle combined with tiragolumab 600 mg IV infusion on Day 1 of each cycle. (Cycle length=21 days) This arm is active, and not recruiting participants.

    Treatment: Atezolizumab, Tiragolumab, and FoundationOne®Liquid CDx

  • Atezolizumab + SY-5609Treatment being tested

    Participants will receive 1680 mg of atezolizumab by IV infusion on Day 1 of each cycle Q4W in repeated 28-day cycles combined with SY-5609 at a dose of 3, 4, 5, 6, 7 or 10 mg by mouth for 7 days, followed by 7 days off. (Cycle length=28 days) This arm is closed.

    Treatment: Atezolizumab, SY-5609, and FoundationOne®Liquid CDx

  • Divarasib + Cetuximab + FOLFOXTreatment being tested

    Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFOX on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.

    Treatment: Cetuximab, Divarasib, FOLFOX, and FoundationOne®Liquid CDx

  • Divarasib + CetuximabTreatment being tested

    Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is active, and not recruiting participants.

    Treatment: Cetuximab, Divarasib, and FoundationOne®Liquid CDx

  • Divarasib + Cetuximab + FOLFIRITreatment being tested

    Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFIRI on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is active, and not recruiting participants.

    Treatment: Cetuximab, Divarasib, FOLFIRI, and FoundationOne®Liquid CDx

  • Divarasib + Bevacizumab + FOLFOXTreatment being tested

    Participants will receive Bevacizumab 5 mg/kg by IV infusion on Days 1 and 15 and FOLFOX on Days 1 and 15 with Divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.

    Treatment: Bevacizumab, Divarasib, FOLFOX, and FoundationOne®Liquid CDx

  • Divarasib + Bevacizumab + FOLFIRITreatment being tested

    Participants will receive Bevacizumab 5 mg/kg by IV infusion on Days 1 and 15 and FOLFIRI on Days 1 and 15 with Divarasib PO QD on Days 1-28. (Cycle length=28 days) This arm is recruiting participants.

    Treatment: Bevacizumab, Divarasib, FOLFIRI, and FoundationOne®Liquid CDx

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Plain-language title
Testing Targeted Treatments in Metastatic Colorectal Cancer by Tumor MarkerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 November 2026